tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BLTE Stock Latest News

Belite Bio price target lowered to $98 from $100 at H.C. Wainwright
The FlyBelite Bio price target lowered to $98 from $100 at H.C. Wainwright
5d ago
BLTE
Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position
PremiumRatings
Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position
7d ago
BLTE
Belite Bio completes Phase 3 DRAGON trial of Tinlarebant
PremiumThe Fly
Belite Bio completes Phase 3 DRAGON trial of Tinlarebant
8d ago
BLTE
Belite Bio announces up to $250M upsized private placement financing
PremiumThe Fly
Belite Bio announces up to $250M upsized private placement financing
12d ago
BLTE
Belite Bio Secures $125 Million in PIPE Financing with Potential for More
PremiumCompany Announcements
Belite Bio Secures $125 Million in PIPE Financing with Potential for More
12d ago
6K
BLTE
Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio
PremiumRatingsPromising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio
1M ago
BLTE
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease
Premium
Ratings
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease
1M ago
BLTE
Belite Bio’s Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Belite Bio’s Earnings Call: Progress Amid Challenges
1M ago
BLTE
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc.
PremiumRatings
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc.
1M ago
BLTE
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth
PremiumCompany Announcements
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth
1M ago
BLTE
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones
PremiumCompany Announcements
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones
1M ago
6K
BLTE
Belite Bio reports Q2 EPS (50c), consensus (42c)
PremiumThe Fly
Belite Bio reports Q2 EPS (50c), consensus (42c)
1M ago
BLTE
Belite Bio, Inc. ADR (BLTE) Q2 Earnings Cheat Sheet
PremiumPre-EarningsBelite Bio, Inc. ADR (BLTE) Q2 Earnings Cheat Sheet
1M ago
BLTE
Belite Bio Announces $15 Million Direct Offering
Premium
Company Announcements
Belite Bio Announces $15 Million Direct Offering
1M ago
6K
BLTE
Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering
Premium
The Fly
Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering
1M ago
BLTE
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential
PremiumRatings
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential
2M ago
BLTE
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations
PremiumRatings
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations
3M ago
BLTE
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant
PremiumCompany Announcements
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant
3M ago
6K
BLTE
Belite Bio completes enrollment in PHOENIX trial
PremiumThe Fly
Belite Bio completes enrollment in PHOENIX trial
3M ago
BLTE
Belite Bio management to meet with Maxim
PremiumThe FlyBelite Bio management to meet with Maxim
4M ago
BLTE
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
Premium
Ratings
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
4M ago
BLTE
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
Premium
Ratings
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
4M ago
BLTE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >